160 related articles for article (PubMed ID: 29474261)
1. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
Bastiaans DET; Geelen SPM; Visser EG; van der Flier M; Vermont CL; Colbers APH; Roukens M; Burger DM; van Rossum AMC;
Pediatr Infect Dis J; 2018 Oct; 37(10):1008-1010. PubMed ID: 29474261
[TBL] [Abstract][Full Text] [Related]
2. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Fletcher CV; Acosta EP;
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):294-296. PubMed ID: 27103489
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years.
Chokephaibulkit K; Prasitsuebsai W; Wittawatmongkol O; Gorowara M; Phongsamart W; Sophonphan J; Kerr SJ; Vanprapar N; Puthanakit T; Pasomsap C; Suwanlerk T; Sekar V; Burger D; Ananworanich J;
Antivir Ther; 2012; 17(7):1263-9. PubMed ID: 22954687
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
8. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
9. Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
[TBL] [Abstract][Full Text] [Related]
10. Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.
Lê MP; Chaix ML; Raffi F; Chevret S; Gallien S; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
Br J Clin Pharmacol; 2019 Jan; 85(1):277-280. PubMed ID: 30421447
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
[TBL] [Abstract][Full Text] [Related]
13. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Calcagno A; Yilmaz A; Cusato J; Simiele M; Bertucci R; Siccardi M; Marinaro L; D'Avolio A; Di Perri G; Bonora S
AIDS; 2012 Jul; 26(12):1529-33. PubMed ID: 22555164
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
[TBL] [Abstract][Full Text] [Related]
16. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
[TBL] [Abstract][Full Text] [Related]
17. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.
Ivanovic J; Bellagamba R; Nicastri E; Signore F; Vallone C; Tempestilli M; Tommasi C; Mazzitelli L; Narciso P
AIDS; 2010 Apr; 24(7):1083-4. PubMed ID: 20386380
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Barrail-Tran A; Yazdanpanah Y; Goldwirt L; Chêne G; Colin C; Piketty C; Bollens D; Katlama C; Descamps D; Molina JM; Fagard C; Taburet AM;
AIDS; 2010 Oct; 24(16):2581-3. PubMed ID: 20960678
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
